Reaction

Hypoproteinaemia reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 1,827 reports · 90 co-occurring drugs

As of the last recalculation, Hypoproteinaemia appears in 1,827 FAERS reports alongside 90 co-occurring drug terms. The strongest observed disproportionality signal is DEXAMETHASONE SODIUM PHOSPHATE (PRR 44.7).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Dexamethasone Sodium Phosphate	39	44.7	44.8
Polatuzumab Vedotin	30	35.6	35.7
Entecavir	35	34.8	34.9
Ganciclovir Sodium	23	25.1	25.1
Ganciclovir	21	23.6	23.7
Mesna Injection	12	16.6	16.7
Sodium Bicarbonate	33	16.4	16.5
Sodium Bicarbonate Injection,	33	16.4	16.5
Mesna	12	16.3	16.4
Acetylcysteine	13	15.8	15.8
Itraconazole	16	15.7	15.8
Amphotericin B	17	15.6	15.6
Febuxostat Tablets 40 Mg	13	14.7	14.7
Febuxostat Tablets 80 Mg	13	14.7	14.7
Meropenem	40	14.5	14.5
Axicabtagene Ciloleucel	12	13.9	14.0
Brentuximab Vedotin	12	13.4	13.4
Blinatumomab	12	13.2	13.2
Busulfan	18	13.2	13.2
Crizotinib	14	12.6	12.6
Methylprednisolone Sodium Succinate	47	11.8	11.8
Human Immunoglobulin G	21	11.7	11.7
Calcium Gluconate	12	11.4	11.4
Cefuroxime	11	11.0	11.0
Granisetron	10	10.9	10.9
Regorafenib	11	10.9	10.9
Amikacin	16	10.8	10.8
Basiliximab	11	10.7	10.7
Voriconazole Injection	19	10.1	10.1
Fexofenadine Hcl	8	9.9	9.9
Voriconazole	26	9.9	9.9
Granisetron Hydrochloride	9	9.9	9.9
Paclitaxel (Aibumin-Bound)	68	9.8	9.8
Valganciclovir Hydrochloride Powder,	10	9.4	9.4
Heparin Sodium	11	9.2	9.2
Magnesium Sulfate In Water For	10	9.0	9.0
Febuxostat	13	8.9	8.9
Valproate Sodium	16	8.9	8.9
Magnesium Sulfate Heptahydrate	10	8.8	8.8
Magnesium Sulfate	10	8.8	8.8
Goserelin	10	8.5	8.5
Anti-Thymocyte Globulin (Rabbit)	6	8.5	8.5
Pegaspargase	9	8.4	8.4
Paclitaxel	70	8.3	8.3
Rifaximin	15	8.2	8.2
Norepinephrine Bitartrate	10	8.0	8.0
Tolvaptan	10	7.9	7.9
Dextrose	9	7.8	7.8
Dextrose Monohydrate	9	7.7	7.7
Ixazomib	19	7.6	7.6
Cytarabine	38	7.3	7.3
Oxaliplatin	46	7.2	7.2
Cyclophosphamide Injection, Solution	106	7.2	7.2
Cyclophosphamide	106	7.2	7.2
Cyclophosphamide For Injection	106	7.2	7.2
Piperacillin Sodium,Tazobactam Sodium	16	6.9	6.9
Carboplatin	74	6.9	6.9
Fludarabine Phosphate	23	6.7	6.7
Micafungin Sodium	5	6.7	6.7
Doxorubicin Hydrochloride	19	6.7	6.7
Pemetrexed Disodium	19	5.7	5.7
Obinutuzumab	8	5.6	5.6
Sunitinib Malate	19	5.6	5.6
Gemcitabine Hydrochloride	25	5.4	5.4
Ado-Trastuzumab Emtansine	4	5.4	5.4
Pemetrexed	10	5.3	5.3
Irinotecan Hydrochloride	6	5.3	5.3
Capecitabine	42	5.3	5.3
Etoposide	32	5.0	5.0
Gemcitabine	17	5.0	5.0
Doxorubicin	38	4.9	4.9
Agalsidase Beta	4	4.9	4.9
Temozolomide	9	4.9	4.9
Cisplatin	33	4.9	4.9
Cabozantinib	20	4.8	4.8
Panitumumab	6	4.4	4.4
Docetaxel Anhydrous	25	4.3	4.3
Docetaxel	25	4.3	4.3
Abiraterone Acetate	15	4.2	4.2
Eltrombopag Olamine	8	4.0	4.0
Durvalumab	7	3.9	3.9
Atezolizumab	13	3.8	3.8
Pazopanib Hydrochloride	9	3.8	3.8
Nivolumab	29	3.5	3.5
Olaparib	6	3.3	3.3
Lenvatinib	9	3.1	3.1
Axitinib	5	2.9	2.9
Pomalidomide	21	2.3	2.3
Icodextrin, Sodium Chloride, Sodium Lactate, Calcium Chloride, Magnesium Chloride	5	1.8	1.8
Cinacalcet Hydrochloride	7	1.7	1.7

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.